These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3924399)

  • 1. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
    Anderson P; Elwin CE
    Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meal-dependent absorption of enteric-coated sodium valproate.
    Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
    Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of a film-coated tablet of valproate in nonfasting volunteers.
    Ishikawa T; Horie M; Furuyama M; Ohuchi M; Awaya A; Sobajima H; Suchi M; Yamaguchi A; Okajima K; Wanibe M
    Jpn J Psychiatry Neurol; 1987 Dec; 41(4):693-8. PubMed ID: 3134567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt.
    Glazko AJ; Chang T; Daftsios AC; Eiseman I; Smith TC; Buchanan RA
    Ther Drug Monit; 1983; 5(4):409-17. PubMed ID: 6419419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
    Hoffmann F; Jancik BC; von Unruh GE
    Arzneimittelforschung; 1986 Jul; 36(7):1118-22. PubMed ID: 3094548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.
    Battino D; Biraghi M; Cusi C; Nespolo A; Avanzini G
    Ital J Neurol Sci; 1982 Oct; 3(3):197-200. PubMed ID: 6819250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
    Johannessen SI; Henriksen O
    Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate.
    Wangemann M; Retzow A; Mazur D; Vens-Cappell B
    Int J Clin Pharmacol Ther; 2000 Aug; 38(8):395-401. PubMed ID: 10984013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
    Garikipati V; Toops DS; Fang Q
    Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).
    Carrigan PJ; Brinker DR; Cavanaugh JH; Lamm JE; Cloyd JC
    J Clin Pharmacol; 1990 Aug; 30(8):743-7. PubMed ID: 2119396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is it preferable to prescribe 1 or 2 daily doses of sodium valproate?].
    Loiseau P; Levy RH; Guyot M; Morselli PL; Brachet-Liermain A
    Nouv Presse Med; 1982 Dec; 11(50):3693-6. PubMed ID: 6820492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical evaluation of hollow type suppositories. V. Preparation of valproic acid suppository and rectal absorption of valproic acid in rabbits.
    Watanabe Y; Tone Y; Nishihara S; Matsumoto M
    J Pharmacobiodyn; 1986 Dec; 9(12):953-61. PubMed ID: 3106614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of valproic acid in man.
    Gugler R; Schell A; Eichelbaum M; Fröscher W; Schulz HU
    Eur J Clin Pharmacol; 1977 Oct; 12(2):125-32. PubMed ID: 336377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of valproate after gastric and direct intestinal administration in rats.
    Yeomans ND; Vajda FJ; Baldas J
    Clin Exp Pharmacol Physiol; 1982; 9(2):173-7. PubMed ID: 6813007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.